Genetic Marker Helps ID Patients With Large B-Cell Lymphoma Unlikely to Benefit From CAR T-Cell Therapy

Patients with relapsed or refractory large B-cell lymphoma can achieve long-term remission after CD19 chimeric antigen receptor (CAR) T-cell therapy. However, more than half of recipients will experience treatment failure. In a new study,  researchers have identified a genetic marker that can help identify patients with large B-cell lymphoma unlikely to benefit from CAR T-cell therapy published in Blood (2022;140[5]:504-515).

Low-pass whole genome sequencing (lpWGS) is a